Allergan Aesthetics has secured EU approval for Boey (trenibotulinumtoxinE), positioning it as the first and only rapid-onset, short-duration neurotoxin for temporary glabellar frown-line improvement in adults. The product differentiates itself through faster onset—results appearing within days rather than the typical 7–14 days for botulinum toxin type A—and shorter duration, making it a distinct clinical profile within the neuromodulator category.